๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Systemic Lupus Erythematosus
Clinical trial register · China

Systemic Lupus Erythematosus Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 33 Nanjing 15 Shanghai 14 Guangzhou 14 Wuhan 11
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
The Children's Hospital of Zhejiang University School of Medicine4 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology4 Chongqing Precision Biotech Co., Ltd3 AstraZeneca3 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School2
Site location
Beijing33 Nanjing15 Shanghai14 Guangzhou14 Wuhan11
All 48 locations
Target enrolment
to

Systemic Lupus Erythematosus trials in China

73 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases
NCT07523282Autoimmune Disease, Systemic Lupus Erythematosus, Systemic Sclerosis (SSc)
DrugHN2302
Shenzhen MagicRNA Biotechnology Co., Ltd
Phase 1
12
Hefei
2026-12-31
Not yet open
SNC116 Therapy for Refractory Systemic Lupus Erythematosus
NCT07748156Systemic Lupus Erythematosus
DrugSNC116
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase EARLY_PHASE1
28
Nanjing
2026-10
Not yet open
A Study of ATG-201 in Adult Participants With Autoimmune Diseases
NCT07732309Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Sjogren's Disease, Autoimmune Diseases
Antengene Biologics Limited
Phase 1
149
Bengbu, Hefei, Beijing, Xiamen, Guangzhou, Luoyang, Zhengzhou, Wuhan
2026-09-01
Not yet open
A Study of QLS2404 Injection in Healthy Participants and Participants With Rheumatic Autoimmune Diseases
NCT07751315Systemic Lupus Erythematosus, Primary Sjรถgren's Syndrome
Qilu Pharmaceutical Co., Ltd.
Phase 1
64
Chengdu
2026-08-11
Not yet open
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
NCT07676266Multiple Sclerosis (MS), Myasthenia Gravis (MG), Neuromyelitis Optica Spectrum Disorder, Systemic Lupus Erythematosus
The Affiliated Hospital of Qingdao University
Phase 1
18
Qingdao
2026-07
Recruiting
A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus
NCT07509892Systemic Lupus Erythematosus
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
198
Bengbu, Bozhou, Beijing, Chongqing, Lanzhou, Guangzhou, Jiangmen, Shenzhen
2026-06-22
Recruiting
Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia
NCT07657793Systemic Lupus Erythematosus, Immune Thrombocytopenia
DrugPaclitaxel
Chinese SLE Treatment And Research Group
Phase 2/3
164
Beijing
2026-06-07
Recruiting
Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases
NCT07558850Rheumatoid Arthritis, Dermatomyositis, Systemic Lupus Erythematosus, Systemic Sclerosis
The First Affiliated Hospital with Nanjing Medical University
Not applicable
72
Nanjing
2026-05-10
By invitation
CHT105 for the Treatment of Refractory Lupus Nephritis
NCT07517536Systemic Lupus Erythematosus, Lupus Nephritis
DrugCHT105
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Not applicable
14
Nanjing
2026-04-22
Recruiting
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
NCT07409181Systemic Lupus Erythematosus
DrugBI 3000202
Boehringer Ingelheim
Phase 2
405
Beijing, Changchun, Changsha, Guangzhou, Linfen, Nanjing, Ningbo, Shanghai
2026-04-20
Recruiting
A Phase 3 Clinical Study of MIL62 in Systemic Lupus Erythematosus
NCT07405970Systemic Lupus Erythematosus
Beijing Mabworks Biotech Co., Ltd.
Phase 3
316
Beijing
2026-04-10
Recruiting
Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for the Treatment of B Cell-Mediated Autoimmune Diseases (SLE and AIHA)
NCT07629596Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia (AIHA)
Circunited BioPharma (Shenzhen) Co., Ltd.
Phase EARLY_PHASE1
5
Beijing
2026-04-07
Recruiting
A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus
NCT07299422Systemic Lupus Erythematosus
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 2
248
Beijing, Shanghai
2026-04-03
Recruiting
A Study of E6742 in Participants With Systemic Lupus Erythematosus
NCT07515014Systemic Lupus Erythematosus
Eisai Co., Ltd.
Phase 2
256
Bengbu, Beijing, Chongqing, Guangzhou, Shantou, Nanning, Guiyang, Luoyang
2026-03-31
Recruiting
MTS109 in Patients With Refractory Autoimmune Diseases
NCT07526350Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Systemic Sclerosis (SSc), ANCA-Associated Vasculitis (AAV)
Shanghai Changzheng Hospital
Phase EARLY_PHASE1
15
Shanghai
2026-03-24
Recruiting
Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
NCT07246096Autoimmune Diseases, Systemic Lupus Erythematosus, Systemic Sclerosis, Primary Sjรถgren Syndrome
Changhai Hospital
Phase EARLY_PHASE1
60
Shanghai
2026-02-20
Recruiting
A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
NCT07363590Systemic Lupus Erythematosus, Rheumatoid Arthritis
DrugMK-1045
Merck Sharp & Dohme LLC
Phase 1
21
Beijing, Luoyang, Wuhan, Shanghai
2026-02-19
Recruiting
A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
NCT07276958Healthy, Systemic Lupus Erythematosus, Rheumatoid Arthritis
Eli Lilly and Company
Phase 1
68
Beijing, Changsha, Hefei, Shanghai, Wenzhou, Wuhan
2026-02-04
Not yet open
A Prospective Comparative Study Involving Multiple Units to Evaluate the Efficacy and Safety of Telitacicept and Belimumab in the Treatment of Systemic Lupus Erythematosus.
NCT07069972Systemic Lupus Erythematosus
Yipeng Liu
Observational
180
Jinan
2026-02-01
Recruiting
Study of CD19 CAR-T Therapy for Refractory SLE
NCT07403097Systemic Lupus Erythematosus
Chongqing Precision Biotech Co., Ltd
Phase 1
18
Chongqing
2026-02
Not yet open
A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases
NCT07212322Systemic Lupus Erythematosus, Idiopahic Inflammatory Myopathies, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Sjรถgren's Syndrome
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
24
Tianjin
2026-01-30
Recruiting
Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE
NCT07318259Systemic Lupus Erythematosus
Chongqing Precision Biotech Co., Ltd
Phase 1
18
Nanjing
2026-01-26
Recruiting
Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE
NCT07331467Systemic Lupus Erythematosus
Chongqing Precision Biotech Co., Ltd
Phase 1
18
Nanjing
2026-01
Recruiting
A Study to Assess the Safety and PK/PD of LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus
NCT07323173Systemic Lupus Erythematosus
Nanjing Leads Biolabs Co.,Ltd
Phase 1
117
Bengbu, Beijing, Guangzhou, Changsha, Nanjing, Pingxiang, Shanghai, Taiyuan
2025-12-16
Recruiting
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
NCT07201558Rheumatoid Arthritis, Systemic Lupus Erythematosus
DrugSurovatamig
AstraZeneca
Phase 1
48
Beijing, Chengdu, Nanjing
2025-12-02
Active, closed
A Comparative Study of the Efficacy and Safety of Telitacicept and Belimumab in the Treatment of Systemic Lupus Erythematosus Involving Multiple Units, Based on Previous Data.
NCT07053137Systemic Lupus Erythematosus, Telitacicept, Belimumab, Efficacy and Safety
Yipeng Liu
Observational
180
Jinan
2025-11-30
Recruiting
An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
NCT07236762Systemic Lupus Erythematosus, Lupus Nephritis (LN), Sjogren's Syndrome, Inflammatory Myopathy
DrugYTS109 cell
China Immunotech (Beijing) Biotechnology Co., Ltd.
Phase 1
18
Bengbu
2025-11-24
Recruiting
Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE
NCT07233642Systemic Lupus Erythematosus
The Children's Hospital of Zhejiang University School of Medicine
Phase 1
18
Hangzhou
2025-11
Recruiting
UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis
NCT07109986Systemic Lupus Erythematosus, Lupus Nephritis
Nanjing IASO Biotechnology Co., Ltd.
Phase 1
21
Nanjing
2025-10-27
Not yet open
Study of CM355 in Patients With Systemic Lupus Erythematosus
NCT07104344Systemic Lupus Erythematosus
Second Xiangya Hospital of Central South University
Not applicable
5
Changsha
2025-09-25
Recruiting
Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease
NCT07077486Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus
DrugsMethylprednisolone·Cyclophosphamide
Tongji Hospital
Phase 4
100
Wuhan
2025-08-25
Recruiting
A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus
NCT06857214Systemic Lupus Erythematosus
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
84
Shanghai
2025-06-04
Not yet open
Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
NCT06970951Systemic Lupus Erythematosus, Rheumatoid Arthritis, Dry Syndrome, Idiopathic Inflammatory Myopathies
DrugUTAA91
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase EARLY_PHASE1
15
Suzhou
2025-05-18
Recruiting
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
NCT06916806Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
DrugAZD5492
AstraZeneca
Phase 1
72
Beijing, Shanghai, Wuhan, Zhengzhou
2025-05-01
Not yet open
UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
NCT06978738Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia, Myasthenia Gravis, Systemic Sclerosis
Changzhou No.2 People's Hospital
Phase 1
18
Changzhou
2025-05
Recruiting
Study of BCMA/CD70 CAR-T Therapy for Refractory cSLE
NCT06934447CAR T Cell Therapy, Systemic Lupus Erythematosus, BCMA
The Children's Hospital of Zhejiang University School of Medicine
Phase 1
18
Hangzhou
2025-04-25
Recruiting
UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Systemic Lupus Erythematosus
NCT06920433Systemic Lupus Erythematosus
Zhejiang University
Phase EARLY_PHASE1
18
Hangzhou
2025-04-08
Active, closed
UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
NCT07155369Systemic Lupus Erythematosus, Systemic Sclerosis
DrugsFludarabine·Cyclophosphamide
The Affiliated Hospital of Xuzhou Medical University
Not applicable
18
Xuzhou
2025-03-18
Recruiting
Efficacy and Safety of HN2301 in Autoimmune Diseases๏ผˆAIDs๏ผ‰
NCT06801119Systemic Lupus Erythematosus, Scleroderma, Rheumatoid Arthritis
Shenzhen MagicRNA Biotechnology Co., Ltd
Phase 1
30
Hefei
2025-03-16
Active, closed
Adjunctive Yu-Tone Music Therapy for Systemic Lupus Erythematosus: a Prospective Cohort Study
NCT06898489Systemic Lupus Erythematosus, Music Therapy
Yijun Luo
Observational
160
Hangzhou
2025-03-01
Not yet open
Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE)
NCT06859931Systemic Lupus Erythematosus
DrugTQB3702
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
120
Bengbu, Hefei, Beijing, Lanzhou, Guangzhou, Shenzhen, Nanning, Langfang
2025-03
Recruiting
CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
NCT06941129Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Inflammatory Myopathy, ANCA-Associated Vasculitis (AAV)
Institute of Hematology & Blood Diseases Hospital, China
Phase 1
12
Tianjin
2025-02-11
Recruiting
CD19/BCMA CAR-T Cell Therapy for Refractory/Moderate-to-severe Systemic Lupus Erythematosus
NCT06349343Systemic Lupus Erythematosus
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1
20
Wuhan
2025-02-10
Not yet open
Study of CM313(SC) Injection in Systemic Lupus Erythematosus(SLE)
NCT06791772Systemic Lupus Erythematosus
DrugCM313
Keymed Biosciences Co.Ltd
Phase 2
150
Beijing
2025-02
Recruiting
BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
NCT06794008Systemic Lupus Erythematosus, Inflammatory Myopathy, Systemic Sclerosis (SSc), ANCA-associated Vasculitis
Peking University People's Hospital
Phase 2
50
Beijing
2024-12-26
Recruiting
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SLE Clinical Research
NCT06711146Systemic Lupus Erythematosus
Zhejiang University
Phase EARLY_PHASE1
36
Hangzhou
2024-12-24
Recruiting
Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects.
NCT06657703Systemic Lupus Erythematosus
DrugHC022
HC Biopharma Inc.
Phase 1
38
Beijing
2024-11-25
Recruiting
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
NCT06617325Systemic Lupus Erythematosus
UCB Biopharma SRL
Phase 3
450
Baotou, Beijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Guangzhou
2024-11-21
Recruiting
Efficacy and Safety of CD19 UCAR T Cells in Refractory Systemic Lupus Erythematosus
NCT06691152Systemic Lupus Erythematosus
The Children's Hospital of Zhejiang University School of Medicine
Phase 1
18
Hangzhou
2024-10-30
Recruiting
A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus
NCT06535412Systemic Lupus Erythematosus
ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
Phase 1/2
218
Beijing
2024-10-10
Active, closed
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
NCT06559163Systemic Lupus Erythematosus
DrugObexelimab
Zenas BioPharma (USA), LLC
Phase 2
190
Hefei, Beijing, Guangzhou, Shenzhen, Shijiazhuang, Nanchang, Pudong, Shanghai
2024-09-17
Recruiting
Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus
NCT06400537Systemic Lupus Erythematosus
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1
25
Wuhan, Taiyuan
2024-07-20
Recruiting
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
NCT06350110Systemic Lupus Erythematosus, Lupus Nephritis, Autoimmune Diseases, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Essen Biotech
Phase 1/2
75
Beijing
2024-07-10
Recruiting
Efficacy and Safety of Telitacicept for Prevention of Flares in SLE Patients
NCT06394063Systemic Lupus Erythematosus
DrugTelitacicept
RenJi Hospital
Not applicable
176
Shanghai
2024-06-28
Recruiting
A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus
NCT06106906Systemic Lupus Erythematosus
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2
15
Wuhan
2024-06-19
Recruiting
Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases
NCT06428188Autoimmune Diseases, Systemic Lupus Erythematosus, Systemic Lupus Erythematosus Acute, Sjogren's Syndrome
Essen Biotech
Phase 1/2
60
Beijing
2024-05-29
Recruiting
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
NCT06133972Systemic Lupus Erythematosus
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
550
Guangzhou, Shantou, Nanjing, Suzhou, Nanchang, Pingxiang, Changchun, Linyi
2024-05-21
Not yet open
A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE)
NCT06340490Systemic Lupus Erythematosus
Guangdong Ruishun Biotech Co., Ltd
Phase 1
24
Beijing, Nanjing, Shanghai
2024-05-15
Recruiting
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
NCT05835310Systemic Lupus Erythematosus
DrugAnifrolumab
AstraZeneca
Phase 3
100
Beijing, Changchun, Changsha, Dongguan, Nanjing, Shanghai, Suzhou, Wenzhou
2024-03-14
Active, closed
Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus
NCT06222853Systemic Lupus Erythematosus, CAR-T Cell Therapy
The Children's Hospital of Zhejiang University School of Medicine
Phase 1
22
Hangzhou
2024-02-10
Recruiting
A Clinical Study of CD19 Universal CAR-ฮณฮดT Cells in Active Systemic Lupus Erythematosus
NCT06106893Systemic Lupus Erythematosus
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 1/2
15
Wuhan
2024-01-12
Recruiting
Safety and Efficacy of Telitacicept in the Treatment of Systemic Lupus Erythematosus (SLE)
NCT06458972Systemic Lupus Erythematosus
Tongji Hospital
Observational
139
Wuhan
2024-01-01
Active, closed
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
NCT05843643Systemic Lupus Erythematosus
DrugUpadacitinib
AbbVie
Phase 3
1,014
Bengbu, Beijing, Xiamen, Guangzhou, Shantou, Nanning, Luoyang, Wuhan
2023-07-25
Active, closed
A Phase 2 Clinical Study of MIL62 in Systemic Lupus Erythematosus
NCT05796206Systemic Lupus Erythematosus
Beijing Mabworks Biotech Co., Ltd.
Phase 2
120
Beijing
2023-05-26
Active, closed
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
NCT05639114Systemic Lupus Erythematosus
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
436
Guangzhou, Shantou, Haikou, Zhuzhou, Nanjing, Suzhou, Nanchang, Pingxiang
2023-03-02
Active, closed
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT05617677Systemic Lupus Erythematosus
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
516
Bengbu, Beijing, Xiamen, Guangzhou, Shenzhen, Baoding, Luoyang, Zhengzhou
2023-01-12
Active, closed
The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)
NCT05540327Systemic Lupus Erythematosus
DrugEnpatoran
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 2
379
Baotou, Beijing, Changchun, Guangzhou, Haikou, Luoyang, Nanchang, Nanjing
2022-09-16
Active, closed
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT04895696Systemic Lupus Erythematosus
Beeline Medicines Corporation
Phase 2
248
Beijing, Shenzhen, Nanjing, Suzhou, Changchun, Dalian, Jinan, Jining
2021-10-11
By invitation
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
NCT04976322Systemic Lupus Erythematosus
UCB Biopharma SRL
Phase 3
760
Beijing, Changchun, Guangzhou, Guilin, Shanghai, Suzhou, Tianjin, Wenzhou
2021-07-27
Active, closed
Efficacy and Safety of Sirolimus in Active Systemic Lupus Erythematosus
NCT04582136Systemic Lupus Erythematosus
DrugPaclitaxel
Chinese SLE Treatment And Research Group
Phase 3
146
Beijing, Shenzhen, Zhengzhou, Nanchang, Shenyang, Kunming
2021-03-04
Recruiting
Long-Term Outcomes in SLE at Peking University People's Hospital
NCT07005479Systemic Lupus Erythematosus
Peking University People's Hospital
Observational
1,000
Beijing
2020-05-21
Recruiting
Treatment and Clinical Outcomes Among SLE Patients in Pregnancy
NCT04976465Systemic Lupus Erythematosus, Pregnancy Related
Qilu Hospital of Shandong University
Phase 1
200
Jinan
2018-01-01
Recruiting
Validation of the Lupus Low Disease Activity State (LLDAS) in the Asia Pacific Region
NCT03138941Systemic Lupus Erythematosus
Monash University
Observational
5,000
Beijing
2013-09-01
Rows per page Showing 1–73 of 73
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/systemic-lupus-erythematosus

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 73 of those studies listing the condition Systemic Lupus Erythematosus.

How many Systemic Lupus Erythematosus trials are recruiting in China?

46 of the 73 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 13 have not yet opened recruitment, 12 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Systemic Lupus Erythematosus), 73 studies
PhaseStudiesRecruitingShare
Phase 1272037%
Phase 211515.1%
Phase 39412.3%
Phase EARLY_PHASE1759.6%
Not applicable628.2%
Observational638.2%
Phase 1/2556.8%
Phase 2/3111.4%
Phase 4111.4%

Most active sponsors

Lead sponsors with the most studies (Systemic Lupus Erythematosus)
Lead sponsorStudiesRecruiting
The Children's Hospital of Zhejiang University School of Medicine43
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology44
AstraZeneca33
Chongqing Precision Biotech Co., Ltd33
Beijing Mabworks Biotech Co., Ltd.21
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.21
Chinese SLE Treatment And Research Group21
Essen Biotech22
Institute of Hematology & Blood Diseases Hospital, China21
Novartis Pharmaceuticals21
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.